Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression

27 Mar 2019

Abstract excerpt

BACKGROUND: Global DNA methylation alterations are hallmarks of cancer. The tumor-suppressive TET enzymes, which are involved in DNA demethylation, are decreased in prostate cancer (PCa); in particular, TET2 is specifically targeted by androgen-dependent mechanisms of repression in PCa and may play a central role in carcinogenesis. Thus, the identification of key genes targeted by TET2 dysregulation may provide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30917865
DOI: 10.1186/s13148-019-0651-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progressionPMID 30917865Read ↗

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancerSemantic proximity Read ↗

TET2 binds the androgen receptor and loss is associated with prostate cancer.Semantic proximity Read ↗

Epigenetic silencing of MEIS2 in prostate cancer recurrenceSemantic proximity Read ↗

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read ↗

The DNA methylation landscape of advanced prostate cancer.Semantic proximity Read ↗

Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumorsSemantic proximity Read ↗

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read ↗

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortalitySemantic proximity Read ↗

Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancerSemantic proximity Read ↗

Clusterin is epigenetically regulated in prostate cancerSemantic proximity Read ↗

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancerSemantic proximity Read ↗

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.